))
008: Big Pharma vs. Low-Cost Cures: Evidence Behind the Claims that Suppression Exists
Manage episode 473973308 series 3649195
Content provided by Kristina Braly. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Kristina Braly or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, we call B.S. on Big Pharma’s profit motives and explore how cheap or off-patent drugs often get sidelined – not by a grand conspiracy, but by a system that simply doesn’t reward low-margin cures. We discuss:
- Opioid Crisis Lawsuits: How Purdue Pharma and others downplayed risks and triggered a national epidemic.
- The Ivermectin Saga: Why a generic anti-parasitic got dismissed for COVID-19, stoking theories about suppressing cheap treatments.
- Cannabis & Psychedelics: Once deemed “no medical value,” now shown to help PTSD, depression, and more, but suppressed for decades.
- Real Influence on Research: Pharma funds trials, buries negative results, and fosters publication bias.
- Minor Mention of LDN: Low Dose Naltrexone as an example of an under-researched, generic therapy that might have big potential.
Key Points & Discussion
- Opioid Crisis Lawsuits:
- Purdue Pharma’s role in pushing OxyContin, concealing addictive potential.
- Billions in settlements; internal memos showed profit-first tactics.
- Demonstrates Big Pharma’s willingness to prioritize sales over safety.
- WHO & Ivermectin Saga:
- Early COVID-19 hype vs. mainstream dismissal, fueling “suppression” talk.
- No major RCT funding from big sponsors – no profits to be made.
- Shows how “lack of data” can be a result of zero corporate interest.
- Cannabis & Psychedelics:
- They were Schedule I (“no medical value”) for decades, but new studies show clear benefits (pain, depression, etc.).
- Pharma’s disinterest in non-patentable compounds – overshadowed by new psych meds.
- Now a resurgence of research as big companies eye synthetic/novel forms for profit.
- Real Influence on Research:
- Evidence of publication bias; negative or unflattering results get hidden.
- Synthroid fiasco (study suppressed for 7 years), paying doctors, lobbying regulators.
- Reinforces that “profit over science” can hamper cheap, off-label therapies.
- LDN (Low Dose Naltrexone) Mention:
- Potential uses (fibromyalgia, Crohn’s), minimal side effects, but no big trials = less adoption.
- Symbolizes how unpatented therapies languish in R&D purgatory.
References
- Opioid Crisis Lawsuits: US DOJ Opioid Settlement with Purdue
- Ivermectin & COVID-19: WHO Advice on Ivermectin
- Cannabis & Psychedelic Studies: Nature: Psilocybin for Depression RCT
- Influence on Research: BMJ: Publication bias in industry-funded trials
- LDN Trials Info: Penn State Crohn's LDN Study
Listener Action Items
- Scrutinize Pharma Claims: Always ask who funds the trials, check for negative or missing data.
- Support Independent Research: Encourage public funding for generics & natural therapies so they're properly studied.
- Stay Skeptical: Don't dismiss everything mainstream, but remember profit motives shape the narrative.
Connect & Subscribe
If you enjoyed this episode, please leave a 5-star review on your favorite podcast platform!
Questions or comments? Email [email protected] or DM us on IG: @icallbswithkb.
Stay tuned for our next episode where we investigate more suspicious BS in the world of medicine, marketing, and beyond!
14 episodes
Share
